BrightInsight Named to Fierce Medtech's 2022 Fierce 15
SAN JOSE, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated...
Stay updated with breaking news from Fierce 15. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN JOSE, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated...
(GH01/ iStock) Quench Bio’s short journey has come to an end after the biotech startup found that its target was simply undruggable. The Cambridge, Massachusetts-based biotech had focused on blocking the gasdermin D protein with oral inhibitors to treat inflammatory diseases and had attempted to seek out a potent, selective chemical series to progress by the first quarter of 2021. It has not, however, managed to hit that goal, and, with credit to the company, it is not trying to spin out this failure, but says it now simply recommends “to wind down and return capital to investors...